Damage, accelerated atherosclerosis, and mortality in patients with systemic lupus erythematosus: Lessons from LUMINA, a multiethnic US cohort

Journal of Clinical Rheumatology

Volumn 13, Issue 6, 2007, Pages 350-353

  Durán, Sergio ^a   González, Luis A ^a   Alarcón, Graciela S ^a,b  

^a University of Alabama at Birmingham   (United States)

^b 830 Faculty Office Tower ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; HYDROXYCHLOROQUINE;

ARTICLE; ATHEROSCLEROSIS; B SCAN; CEREBROVASCULAR ACCIDENT; COMPUTER ASSISTED TOMOGRAPHY; CONGESTIVE HEART FAILURE; DISEASE DURATION; HEART INFARCTION; HUMAN; LONG TERM CARE; MORTALITY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SOCIAL STATUS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ATHEROSCLEROSIS; DISEASE PROGRESSION; ETHNIC GROUPS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MORBIDITY; RISK FACTORS; SURVIVAL RATE; UNITED STATES;

EID: 37849025863     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/RHU.0b013e31815d23ad     Document Type: Article

References (26)

1. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.
2. Urowitz MB, Bookman AA, Koehler BE, et al. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med. 1976;60:221-225.
3. Bernatsky S, Boivin JF, Joseph L, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006;54:2550-2557.
4. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am J Epidemiol. 1997;145:408-415.
5. Ward MM. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum. 1999;42:338-346.
6. Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001;44:2331-2337.
7. Manzi S, Selzer F, Sutton-Tyrrell K, et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum. 1999;42:51-60.
8. Asanuma Y, Oeser A, Shintani AK, et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003;349:2407-2415.
9. Gladman DD, Goldsmith CH, Urowitz MB, et al. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol. 2000;27:373-376.
10. Alarcon GS, McGwin G Jr, Bartolucci AA, et al. Systemic lupus erythematosus in three ethnic groups. IX. Differences in damage accrual. Arthritis Rheum. 2001;44:2797-2806.
11. Fernandez M, Alarcon GS, Calvo-Alen J, et al. A multiethnic, multicenter cohort of patients with systemic lupus erythematosus (SLE) as a model for the study of ethnic disparities in SLE. Arthritis Rheum. 2007;57:576-584.
12. Alarcón GS, McGwin G Jr, Bastian HM, et al. Systemic lupus erythematosus in three ethnic group VII: Predictors of early mortality in the LUMINA cohort. Arthritis Rheum. 2001;45:191-202.
13. Urowitz MB, Gladman DD, Abu-Shakra M, et al. Mortality studies in systemic lupus erythematosus. Results from a single center. III. Improved survival over 24 years. J Rheumatol. 1997;24:1061-1065.
14. Sacks JJ, Helmick CG, Langmaid G, et al. Trends in deaths from systemic lupus erythematosus-United States, 1979-1998. MMWR. 2002;51:371-374.
15. Kasitanon N, Magder LS, Petri M. Predictors of survival in systemic lupus erythematosus. Medicine (Baltimore). 2006;85:147-156.
16. Toloza SMA, Uribe AG, McGwin G Jr, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA) XXIII: baseline predictors of vascular events. Arthritis Rheum. 2004;50:3947-3957.
17. Szalai AJ, Alarcón GS, Calvo-Alén J, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXX: Association between C-reactive protein (CRP) gene polymorphisms and vascular events. Rheumatology. 2005;44:864-868.
18. Alarcon GS, Roseman JM, McGwin G Jr, et al. Systemic lupus erythematosus in three ethnic groups: XX. Damage as predictor of further damage. Rheumatology. 2004;43:202-205.
19. Andrade RM, Alarcon GS, Fernandez M, et al. Accelerated damage accrual among men with systemic lupus erythematosus: XLIV. Results from a multiethnic US cohort. Arthritis Rheum. 2007;56:622-630.
20. Fessler BJ, Alarcón GS, McGwin G Jr, et al. Systemic lupus erythematosus in a multiethnic group: XVI. Hydroxychloroquine usage is associated with a lower risk of damage accrual. Arthritis Rheum. 2005;52:1473-1480.
21. Fessler BJ, McGwin G Jr, Roseman JM, et al. Hydroxychloroquine (HCQ) usage is associated with decreased renal and cardiovascular damage in patients with systemic lupus erythematosus (SLE). Arthritis Rheum. 2001;44:S201.
22. Landewe RB. The benefits of early treatment in rheumatoid arthritis: confounding by indication, and the issue of timing. Arthritis Rheum. 2003;48:1-5.
23. Alarcon GS, McGwin G Jr, Bertoli AM, et al. Effect of hydroxychloroquine in the survival of patients with systemic lupus erythematosus. Data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis. 2007;66:1168-1172.
24. Andrade RM, Alarcon GS. Antimalarials in systemic lupus erythematosus: benefits beyond disease activity. Future Rheumatol. 2006;1:225-233.
25. Bruce IN. Cardiovascular disease in lupus patients: should all patients be treated with statins and aspirin? Best Pract Res Clin Rheumatol. 2005;19:823-838.
26. Petri M, Kiani AN, Post W, et al. Lupus atherosclerosis prevention study (LAPS): a randomized double blind placebo controlled trial of artovastatin versus placebo. Arthritis Rheum. 2007;54:S520.